Modulation of TNF Induced Skin Inflammation

The current therapies for skin inflammatory diseases have either significant risk of adverse effectthem, as in the case of corticosteroids, are ineffectual e.g. prostaglandin and leukotriene inhibitoof inflammation, e.g. vitamin D3 analogs. systemic inflammatory diseases are currently being targeteproinflammatory cytokine antibodies and receptor/ binding proteins. Tumor necrosis factor alpha (TNFattention and encouraging studies have been reported in the treatment of rheumatoid arthritis, inflaand metastatic Crohn's disease. Unfortunately, these therapies are not suited to treating skin diseainherent in the delivery of large molecules through the stratum corneum of the skin, the very largesystemic delivery, and cost-effectiveness. Elevated levels of TNP have been recently found in psoriareason to believe that TNT is involved also in atopic dermatitis and allergic contact dermatitis. Thidentifying small drugs that are being marketed for non-inflammatory uses and which potently inhibitinflammatory cells and epidermis and suppress swelling and TNF expression in mouse models of skin indiseases.